Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
04:35pm, Friday, 29'th May 2026
Company Announcement COPENHAGEN, Denmark; May 29, 2026 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, th
Media Release COPENHAGEN, Denmark; May 21, 2026 Twenty-three abstracts will highlight the versatility and strength of Genmab's portfolio and pipeline, including data from the comprehensive epcoritamab
Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript
08:43am, Thursday, 14'th May 2026
Genmab A/S (GMAB) Q1 2026 Earnings Call Transcript
Capital Increase in Genmab as a Result of Employee Warrant Exercise
01:46pm, Tuesday, 12'th May 2026
Company Announcement COPENHAGEN, Denmark; May 12, 2026 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 2,346 shares as a consequence of the exercise of employee warrants. The increase
Genmab Announces Financial Results for the First Quarter of 2026
11:02am, Thursday, 07'th May 2026
May 7, 2026 Copenhagen, Denmark; Interim Report for the Three Months Ended March 31, 2026 Highlights Genmab revenue increased 25% compared to the first three months of 2025 , to $896 million FDA appro
Genmab A/S Share Capital Reduction
10:56am, Friday, 17'th Apr 2026
Company Announcement COPENHAGEN, Denmark; April 17, 2026 – Genmab A/S (Nasdaq: GMAB) At Genmab A/S' Annual General Meeting on March 19, 2026, it was decided to reduce the Company's share capital wit
Major Shareholder Announcement
10:44am, Tuesday, 14'th Apr 2026
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 14, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Marke
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
06:23am, Tuesday, 14'th Apr 2026
Company Announcement Net sales of DARZALEX ® in the first quarter of 2026 totaled USD 3,964 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen
Media Release COPENHAGEN, Denmark; April 13, 2026 Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S ® ) and bevacizumab was tolerable, with no new safety signals in
Genmab: Multiple Binaries Could Alter The Thesis
12:56pm, Thursday, 09'th Apr 2026
Genmab faces a pivotal transition as DARZALEX royalties end by 2029–2032, but multiple late-stage oncology catalysts could redefine its growth trajectory. Upcoming registrational readouts for EPKINL
JPMorgan Chase & Co. Decreases Position in Genmab A/S Sponsored ADR $GMAB
04:57am, Saturday, 04'th Apr 2026
JPMorgan Chase and Co. decreased its position in shares of Genmab A/S Sponsored ADR (NASDAQ: GMAB) by 87.3% during the third quarter, according to the company in its most recent disclosure with the Se
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
03:19pm, Wednesday, 01'st Apr 2026
Company Announcement COPENHAGEN, Denmark; April 1, 2026 – Genmab A/S (Nasdaq: GMAB) - This document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees a
Major Shareholder Announcement
03:24am, Wednesday, 01'st Apr 2026
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; April 1, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Market
Major Shareholder Announcement
12:00pm, Monday, 30'th Mar 2026
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; March 30, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Marke
Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, and, as we mentioned before, it all depends on the status of the war with Iran and the price of oil o
